i&i Biotech Fund’s Post

💊 Our institute has long been working to cultivate the path of scientific discovery into practice, and we have also surpassed several milestones in this regard over the past year. In June 2024, Adalid Sciences, a Czech biotechnology company linked to IOCB, entered the global gene therapy field thanks to the support from BTL Medical & Healthcare Technologies. The company leverages technologies from IOCB laboratories to advance global gene therapy and bring groundbreaking research closer to patients. Last but not least, a translational center #PharmTheon in Prague’s Harfa district opened its state-of-the-art laboratories in April 2024. The center accelerates the transformation of promising molecules into potential drugs. i&i Prague, biotechnology incubator from IOCB Tech family, continued to support the commercialization of unique scientific ideas. The year 2024 was marked by piloting a new incubation program and mapping foreign markets. In addition, as a co-organizer, i&i Prague participated in the organization of the 2nd annual Prague.bio Conference, which took place in Prague at the end of September. Related i&i Biotech Fund, of which i&i Prague is a limited partner, also continued to seek out and support the unique life science projects from Central Europe. Several promising startups were added to its portfolio, which have the potential to bring new solutions in the fields of drug discovery, diagnostics, and medtech. Furthermore, the 10th Prague–Weizmann Summer School for Drug Discovery and Development from Basic Research to Clinical Trials was also co-organized by IOCB Prague, University of Chemistry and Technology in Prague (UCT Prague), and the Weizmann Institute of Science, with financial support of IOCB Tech. Prague Summer school welcomed 141 participants from 20 countries. See more ► uochb.cz/en/news/605 & uochb.cz/en/news/617 ⤵️   #iocb #iocbprague #akademievedcr #yearinreview #year2024

𝐆𝐞𝐧𝐨𝐦𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐰𝐨𝐫𝐭𝐡 $83.1 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 2028 Download PDF Brochure @ https://lnkd.in/dewagMrX The global 𝐠𝐞𝐧𝐨𝐦𝐢𝐜𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐢𝐧 𝐭𝐞𝐫𝐦𝐬 𝐨𝐟 𝐫𝐞𝐯𝐞𝐧𝐮𝐞 𝐰𝐚𝐬 𝐞𝐬𝐭𝐢𝐦𝐚𝐭𝐞𝐝 𝐭𝐨 𝐛𝐞 𝐰𝐨𝐫𝐭𝐡 $46.2 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 2023 𝐚𝐧𝐝 𝐢𝐬 𝐩𝐨𝐢𝐬𝐞𝐝 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 $83.1 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 2028, 𝐠𝐫𝐨𝐰𝐢𝐧𝐠 𝐚𝐭 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 12.4% from 2023 to 2028 In Septembe, 𝐐𝐈𝐀𝐆𝐄𝐍 (𝐆𝐞𝐫𝐦𝐚𝐧𝐲) 𝐚𝐧𝐝 𝐍𝐞𝐮𝐫𝐨𝐧23 𝐈𝐧𝐜. (𝐔𝐒), an early-stage biotechnology company engaged in developing precision medicine for genetically defined neurological and #immunologicaldiseases, entered into an agreement to develop a #companiondiagnostic for Neuron23’s brain penetrant leucine-rich repeat kinase (LRRK2) inhibitor for #Parkinson’sdisease. In May , 𝐈𝐥𝐥𝐮𝐦𝐢𝐧𝐚 (𝐔𝐒) announced a long-term strategic partnership with Janssen to accelerate the development of precision medicine. Through this partnership, Illumina will support drug discovery with whole-genome sequencing (WGS) and other multi-omic methodologies using Illumina Lab Services. Such developments are indicative of the significant opportunities related to the use of #NGS in #precisionmedicine and #moleculardiagnostics. 𝐄𝐧𝐭𝐞𝐫𝐩𝐫𝐢𝐬𝐞𝐬 𝐨𝐩𝐞𝐫𝐚𝐭𝐢𝐧𝐠 𝐰𝐢𝐭𝐡𝐢𝐧 𝐭𝐡𝐢𝐬 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐲: 54gene     Nucleome Informatics Pvt Ltd      eBioscience      BioLizard      Eurogentec      IITA-BIOSCIENCE CENTER      Genomic Prediction   Celldom, Inc.   MacroGenics, Inc.      Earlham Institute      MyFloraDNA Inc.      Accelevir Diagnostics      Genomize      Haystack MRD™ by Quest Diagnostics®      Biokart India Pvt. Ltd.      PT Sciencewerke      Eurofins India    Biosearch Technologies, Inc     Takara Bio Europe     ArrayGen Technologies Private Limited      Novogene BioDiscovery      Myllia Biotechnology      Microbion     Curiox Biosystems      SeqOne Genomics      Biogem Istituto di Biologia e genetica molecolare      GV20 Therapeutics      Gnosko Bio     Biotron Healthcare (India) Pvt. Ltd      NoorDx - Diagnostics & Discovery      ReviR Therapeutics     Single Cell Discoveries      Flomics Centrillion Technology, Inc.      Geneos Therapeutics     Genomic Vision    Tavros Therapeutics      Scipio bioscience   

🧬 𝐓𝐡𝐞 𝐅𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞 𝐢𝐬 𝐇𝐞𝐫𝐞: 𝐆𝐞𝐧𝐞 𝐄𝐝𝐢𝐭𝐢𝐧𝐠 𝐑𝐞𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧 Download PDF Brochure: https://lnkd.in/dhNcBXqW Fascinating how we've moved from merely reading our genetic code to precisely editing it! The gene editing market is undergoing explosive growth, expected to reach $7.59B by 2029. Here's why this matters: CRISPR, ZFNs, and TALENs aren't just scientific tools – they're opening doors to treating previously incurable genetic diseases. Think of them as molecular scissors, each with unique precision in cutting and modifying DNA. What excites me most is the real-world impact. We're seeing promising clinical trials for conditions like sickle cell disease and certain forms of blindness. This isn't science fiction anymore – it's science fact. But beyond medicine, these technologies are revolutionizing: • Agriculture: Creating more resilient crops • Biotechnology: Engineering microorganisms for sustainable solutions • Drug Development: Accelerating the discovery of new treatments The most thrilling part? We're just scratching the surface. With a 10.2% CAGR, we're witnessing the birth of a new era in healthcare. 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞: Merck KGaA, Darmstadt, Germany, Thermo Fisher Scientific, GenScript, Agilent Technologies, PerkinElmer, Lonza, Tecan, Sangamo Therapeutics, Inc., Editas Medicine, CRISPR Therapeutics, Precision BioSciences, Inc., Cellectis, Intellia Therapeutics, Inc., bluebird bio, Regeneron, AMSBIO, Creative Biogene, Synthego Corporation, and Beam Therapeutics Other Companies that are Operating in this Market Globally: Gene Logic Taysha Gene Therapies Rocket Pharmaceuticals Telesis Bio Tune Therapeutics Capsida Biotherapeutics Prevail Therapeutics MaxCyte, Inc. 2seventy bio Aliri Bioanalysis Ascidian Therapeutics Akouos Brammer Bio Santa Cruz Biotechnology (SCBT) Eurofins Genomics Americas      Biologics Consulting Orchard Therapeutics - U.S. GENETiKS GLOBAL - Genetic Diagnostic Center and Laboratories   MeiraGTx BioNTech IMFS #Biotech #GeneEditing #CRISPR #FutureOfMedicine #Healthcare #Innovation #BioScience #MedTech #Research #Science

🧬 Metagenomi Raises $175M Series B for Next-Gen Gene Editing TL;DR: • Secured $175M despite challenging biotech market • Led by PFM Health Sciences, Farallon Capital, with Moderna & BMS participating • Advancing novel CRISPR technologies beyond Cas9 • Developing in vivo & ex vivo therapies for hemophilia, kidney diseases & cancer In a remarkable display of investor confidence, UC Berkeley spinout Metagenomi has raised $175M to revolutionize gene editing technology. This follows their strategic partnership with Moderna, highlighting the company's growing influence in precision medicine. The funding round attracted elite biotech investors, including Moderna, Bristol Myers Squibb, and Novo Nordisk's parent company, demonstrating strong institutional backing for Metagenomi's innovative approach to genome engineering. What sets them apart? Metagenomi is mining microbial DNA to discover new CRISPR enzymes that could surpass current Cas9 capabilities, potentially unlocking treatments for previously untargetable diseases. The funds will accelerate preclinical research and enhance delivery systems through their collaboration with Moderna's lipid nanoparticle expertise. 💭 What are your thoughts on the future of gene editing technologies? How might these advances reshape therapeutic development in the next decade? #Biotech #GeneEditing #CRISPR #BiotechInnovation #PrecisionMedicine #intelligencesimplified #pharma #biotech #biodatastudio

𝐄𝐱𝐩𝐥𝐨𝐫𝐢𝐧𝐠 𝐆𝐫𝐨𝐰𝐭𝐡 𝐓𝐫𝐞𝐧𝐝𝐬 𝐢𝐧 𝐎𝐥𝐢𝐠𝐨𝐧𝐮𝐜𝐥𝐞𝐨𝐭𝐢𝐝𝐞 𝐒𝐲𝐧𝐭𝐡𝐞𝐬𝐢𝐬 𝐆𝐞𝐭 𝐚 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐆𝐮𝐢𝐝𝐞: https://lnkd.in/d9YjaYyJ The Oligonucleotide Synthesis market is rapidly expanding, driven by advancements in genomics, therapeutics, and personalized medicine. With applications ranging from research to diagnostic and therapeutic areas, oligonucleotides are critical components in drug development, gene editing, and molecular diagnostics. Key growth drivers include: • Increased R&D in Biotechnology: As demand for targeted therapies grows, the need for oligonucleotide synthesis has surged. • Gene Therapy and CRISPR Technologies: These technologies are revolutionizing how we approach genetic diseases, further fueling the market. • Strategic Collaborations: Pharmaceutical companies and academic institutions are forming partnerships to develop next-gen oligo-based therapies. Challenges like cost efficiency and regulatory hurdles remain, but innovations in automated synthesis platforms and purification methods are addressing these concerns. With a projected CAGR of 13.22%, the future looks promising for stakeholders in this space. 💡 Key Players:  Thermo Fisher Scientific Merck KGaA, Darmstadt, Germany Danaher Corporation Dharmacon Agilent Technologies Bio Synthesis Eurogentec LGC Biosearch Technologies Biolegio Twist Bioscience #OligonucleotideSynthesis #MolecularBiology #Biotechnology #DNA #RNA #Genomics #LifeSciences #SyntheticBiology #NucleicAcids #GeneticResearch #OligonucleotideSynthesis #MolecularBiology #Biotechnology #DNA #RNA #Genomics #LifeSciences #SyntheticBiology #NucleicAcids #GeneticResearch

The "world model of a cell", or a "virtual cell", or "AI-powered in-silico" cell, is closer than ever. Perturbation data is needed to train the model, and this data is emerging fast.

CHA Bio Group said it signed a #memorandum of understanding with the Cambridge Innovation Center (CIC) in Boston to establish an open innovation center equipped with a cell gene biobank (CGB) in Korea. To learn more: https://lnkd.in/dEGCUMFF #Biobank #Biobanking #Genomics #Korea #Biotechnology #Medical #Research #GeneTherapy #Pangyo CHA Bio Group｜차바이오그룹 | Korea Biomedical Review

Can AI predict CRISPR perturbation outcomes across different cell types? At Myllia Biotechnology, we are addressing this challenge with a unique large-scale CROP-Seq dataset, systematically perturbing 218 genes across six cellular backgrounds. This dataset provides a critical resource for AI-driven Foundation Models of the Human Cell, helping them learn how different cellular environments influence the response to genetic perturbations. Why does this matter? Drug target discovery often relies on simplified models, like cancer cell lines, because many biologically relevant cell types can’t be studied directly with CRISPR. The ability to transfer knowledge from one cell type to another—a concept known as context transfer—could revolutionize AI-powered drug discovery. To tackle this, we created a systematic CROP-Seq dataset covering: THP-1 (monocytes, macrophages M0, macrophages M1), Jurkat, K562, A549, U2OS and HCT116 cells. “This dataset allows AI/ML models to understand how cellular background affects gene perturbation responses,” explains Myllia's CSO, Tilmann Burckstummer. “It’s a key step toward fine-tuning AI-driven models for drug discovery.” With 30+ CROP-Seq projects and 150+ CRISPR screens completed, Myllia Biotechnology is the global leader in CRISPR-based functional genomics screening. Want to leverage our dataset for AI-driven drug discovery? Our CROP-Seq datasets are available for licensing—reach out to info@Myllia.com or learn more here: https://lnkd.in/d2cJEiC9 #FunctionalGenomics #MylliaBio #CROPSeq #CRISPR #DrugDiscovery #MachineLearning #aiinbiology #perturbseq

🌟 𝗦𝗽𝗼𝘁𝗹𝗶𝗴𝗵𝘁 𝗼𝗻 𝗢𝘅𝗳𝗼𝗿𝗱’𝘀 𝗟𝗶𝗳𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲 𝗦𝗲𝗰𝘁𝗼𝗿 🌟 It’s always important to acknowledge the inspiring progress happening across the life science industry here in the UK. As one of the leading biotech hubs, Oxford consistently delivers on innovation and global partnerships. Here’s a snapshot of some exciting updates from the region: 📈 Oxford Biomedica is in talks to acquire ABL Europe, a move that would bolster its cell and gene therapy manufacturing capabilities across Europe—a huge step forward for advancing biopharma production on a global scale. 💡 Oxford Nanopore Technologies received a £50 million investment from Novo Holdings, boosting its pioneering real-time DNA/RNA sequencing technology. This is expected to propel new drug discovery and delivery solutions, further cementing its role in cutting-edge molecular analysis. 🤝 Evox Therapeutics Ltd entered a transformative $882 million alliance with Takeda Pharmaceuticals. Together, they’ll develop protein replacement and mRNA therapies for rare diseases, utilizing Evox’s breakthrough exosome delivery platform. Each of these milestones highlights Oxford’s pivotal role in driving forward-looking biotech solutions. Excited to see such impactful contributions emerging from our local life science landscape! 🗣 Tiagh Lawrence #LifeSciences #UKBiotech #Oxford #Innovation #Pharma #Biotech #Healthcare #Collaboration

New Funding Opportunity! Target ALS is excited to announce a new grant opportunity for consortia developing novel modalities as therapeutics for ALS. This funding call for collaborative groups aims to facilitate the discovery and development of molecules targeting RNA/DNA to drive innovation in ALS treatment. What We're Funding: - Development of new antisense oligonucleotide chemistries, CRISPR, Zinc Finger, siRNA, and more. - Enhanced brain delivery platforms like lipid nanoparticles, AAV, and others. - Molecules with demonstrated cell-based activity needing additional validation - Modalities applied to an ALS-associated genetic target Key Dates: LOI due: November 18, 2024 Full proposals due: February 21, 2025 Funding begins: May 2025 This grant is an exciting opportunity to collaborate with academic and industry partners to accelerate breakthroughs in ALS research. Learn more and apply: https://bit.ly/4eQHsMl #ALSResearch #GrantOpportunity #GeneTherapies #InnovativeScience #TargetALS #EveryoneLives